Overcoming Biologic Concerns and Achieving Remission in IBD

This episode, titled “Overcoming Biologic Concerns and Achieving Remission in IBD,” features panelists discussing the patient experience with starting biologic therapy and navigating concerns related to long-term treatment in inflammatory bowel disease (IBD). The patient panelist reflects on initial fears surrounding biologic therapy, including concerns about long-term safety and potential side effects, while emphasizing the importance of trust, communication, and ongoing support from the care team throughout treatment. The panel also highlights the value of routine monitoring, follow-up appointments, and patient engagement in long-term disease management.

Throughout the discussion, expert faculty explored how clinicians counsel patients when introducing biologic therapies and discussed expectations surrounding treatment response and symptom improvement. The patient panelist shares experiences with guselkumab therapy, including early symptom relief, improved tolerance of meals, reduced gastrointestinal urgency, and meaningful improvements in day-to-day comfort and functioning. The panel also reviews the importance of timely treatment adjustments when previous therapies do not adequately control disease activity or are associated with adverse effects.

In addition, the conversation emphasizes how effective biologic therapy can improve quality of life and help patients regain a sense of normalcy while living with IBD. Expert faculty discuss how rapid symptom control, safety monitoring, and individualized care contribute to positive treatment experiences and long-term remission. The panel concludes by highlighting the importance of shared decision-making and patient confidence when initiating biologic therapy for IBD.

In the next episode, “Treatment Goals and Long-Term Remission in IBD,” panelists will discuss how clinicians monitor treatment response in IBD using symptom improvement, biomarkers, and endoscopic healing. The panel will also highlight how treatment goals, safety, access, and patient lifestyle considerations can influence biologic therapy selection and long-term disease management.